Detects human DC‑SIGN in direct ELISAs and Western blots. Was reported to cross-react with human DC‑SIGNR as well as DC‑SIGN from Pigtailed Macaque and Rhesus Macaque (10).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG_2A

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Applications for Human DC-SIGN+DC-SIGNR Antibody

Application

Recommended Usage

Adhesion Blockade

The adhesion of NIH-3T3 mouse embryonic fibroblast cells (5 x 10⁴ cells/well) to immobilized Recombinant Human ICAM-3/CD50 Fc Chimera (Catalog # 715-IC, 10 µg/mL, 100 µL/well) was maximally inhibited (80-100%) by 4 µg/mL of the antibody.

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

2.5 µg/10⁶ cells
Sample: Human DC‑SIGN transfected 3T3 mouse embryonic fibroblast cell line

Western Blot

1 µg/mL
Sample: Recombinant Human DC-SIGN Fc Chimera (Catalog # 161-DC)
Recombinant Human DC-SIGNR/CD299 Fc Chimera (Catalog # 162-D2)

Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: DC-SIGN+DC-SIGNR

DC-SIGN (Dendritic Cell- Specific ICAM-3 Grabbing Non-Integrin) has been shown to play an important role in regulating dendritic cell (DC) and T cell interactions, including antigen presentation to T cells and enhancement of transinfection of CD4+ T cells by HIV-1 (1, 2). Efforts to identify additional type II membrane proteins resulted in the isolation of a molecule related in sequence to DC-SIGN known as DC-SIGNR (DC-SIGN Related) (3, 4). DC-SIGNR shares 73 - 80% amino acid homology with DC-SIGN and is located on human chromosome 19p13.3. Its structure is similar to DC-SIGN and therefore binds mannose residues in a calcium dependent fashion, including ICAM-3 and HIV-1 gp120 (5). DC-SIGNR, also known as L-SIGN (Liver/Lymph node-Specific ICAM-3-Grabbing Non-integrin) and DC‑SIGNR, is polymorphic since allelic variations of the exon 4 encoded sequence have been isolated (5). This is further supported by a study demonstrating the ability to isolate a large repertoire of DC-SIGNR transcripts largely the result of alternative splicing of the 7 coding exons (6). L-SIGN/DC-SIGNR is primarily transcribed in the liver and lymph nodes but not in monocyte derived DC (5). Expression of L-SIGN/DC-SIGNR is restricted to endothelial cells derived from liver sinusoids, lymph nodes sinuses and capillaries (7) although variable expression in placenta and some monocytic cell lines has also been reported, including both membrane and soluble isoforms of the protein (6). Expression of DC-SIGN is induced during the in-vitro generation of DC from either monocytes or bone marrow progenitors, with maximal surface expression at day 7 of culture (1). Immature DC in the skin and mature DC in the tonsil have been demonstrated to express DC‑SIGN (8). Analysis of various tissues and cell lines suggests that DC-SIGN expression is restricted to DC (1) although a more recent report finds evidence of expression in placenta, resting monocytes and monocytic cell lines (6). This discrepancy may be partially related to the multiple isoforms of DC-SIGN transcripts, including both membrane and soluble forms, as well as exon splice variants reported in the latter study (6). A detailed description of the additional properties of this monoclonal antibody may be found in references 9 and 10.

References

Geijtenbeek, T.B.H. et al. (2000) Cell 100:575.
Geijtenbeek, T.B.H. et al. (2000) Cell 100:587.
Yokoyama-Kobayashi, M.T. et al. (1999) Gene 228:161.
Soilleux, E.J. et al. (2000) J. Immunol. 165:2937.
Bashirova, A.A. et al. (2001) J. Exp. Med. 193:671.
Mummidi, S. et al. (2001) J. Biol. Chem., 2001 May 3 [epub ahead of print].
Pohlman, S. et al. (2001) Proc. Natl. Acad. Sci. USA 98:2670.
Geijtenbeek, T.B.H. et al. (2000) Nature Immunol. 1:353.
Wu, L. et al. (2002) J. Virol. 76:5905.
Baribaud, F. et al. (2002) J. Virol. 76:9135.

Long Name

Dendritic Cell-specific ICAM-3-grabbing Non-integrin

Alternate Names

DCSIGN+DCSIGNR

Entrez Gene IDs

30835 (Human)

Gene Symbol

CD209

Additional DC-SIGN+DC-SIGNR Products

Product Documents for Human DC-SIGN+DC-SIGNR Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human DC-SIGN+DC-SIGNR Antibody

For research use only

Citations
Reviews

Calculators
Flow Cytometry

Human DC-SIGN+DC-SIGNR Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB16211

Key Product Details

Species Reactivity

Validated:

Cited:

Applications